On July 9, AstraZeneca fell 8.21% in pre-market trading, trading at approximately $173.19 per share, with turnover of $64.5 thousand.

On the news front, AstraZeneca's WAINUA, a drug targeting neurological diseases, failed to meet its primary endpoint in a late-stage clinical trial, triggering a sharp selloff. WAINUA represents a key pipeline asset in the company's neurology portfolio, and the clinical failure introduces significant uncertainty around its commercialization prospects. European-listed shares of AstraZeneca fell as much as 9% on the same news.

Notably, the decline is company-specific rather than sector-wide. Within the Pharmacy sector, peers traded largely flat, with Eli Lilly up 0.22%, Pfizer up 0.27%, Merck up 0.04%, while Johnson & Johnson dipped 0.46% and Crinetics Pharmaceuticals fell 0.35%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)